Glutorlix M 2 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 1000 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and increases peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The prolonged-release formulation ensures a steady plasma concentration, optimizing therapeutic efficacy while minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Glutorlix M 2 Forte is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve target blood glucose levels. This medication should be used as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose, renal function, and potential adverse effects is essential. Glutorlix M 2 Forte Tablet PR offers an effective dual mechanism approach to glycemic control, improving patient compliance through once-daily dosing and sustained drug release.